- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03432247
Pain Management Support Study for Patients With Advanced Cancer
February 18, 2022 updated by: Joke Bradt, Drexel University
Mechanisms of Music Therapy to Palliate Pain in Patients With Advanced Cancer
Chronic pain is one of the most feared symptoms in people with cancer.
Insufficient relief from pharmacological treatments and the fear of side effects are important reasons for the growing use of complementary pain management approaches in cancer care.
On such approach is music therapy.
Although several studies have demonstrated that music therapy interventions can reduce pain in people with cancer, few studies have examined the therapeutic mechanisms that explain how music therapy interventions lead to improved pain management.
The purpose of this study is to examine whether an interactive music therapy intervention improves psychological and social factors that play an important role in chronic pain management in people with advanced cancer.
The findings will contribute towards the optimization of music therapy for palliation of chronic pain in people with advanced cancer.
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Detailed Description
This study addresses the public health problem of chronic pain as one of the most feared symptoms in people with cancer, with 70% to 90% of patients with advanced disease reporting pain.
Unrelieved pain remains a challenge in cancer care.
Insufficient relief from pharmacological treatments and the fear of side effects are important reasons for the growing use of complementary pain management approaches in people with cancer.
One such approach is music therapy.
Although efficacy of music therapy for pain has been established, there are no mechanistic studies clarifying how it works in clinical populations.
Thus, there is a lack of knowledge related to 1) therapeutic mechanisms that lead to improvement (mediator effects) and 2) the relationship between patient characteristics and treatment response (moderator effects).
Yet, it is well accepted that knowledge of mediators and moderators as well as a validated theory of action (i.e., how the intervention activates the mediators) are needed to optimize psychosocial treatment interventions.
Therefore, the overarching goals of this study are to 1) examine mediators and moderators hypothesized to account for the pain-reducing effects of Interactive Music Therapy (IMT) in people with advanced cancer and chronic pain and 2) validate IMT's theory of action.
The mediation model to be tested in this study aligns with a biopsychosocial framework to palliation of chronic pain and is based on findings from a preliminary study.
The investigators postulate that anxiety, mood, self-efficacy and perceived support mediate the effects of IMT on pain outcomes (i.e.
pain intensity and pain interference).
In addition, the impact of several moderators on the hypothesized mediation model, namely adult playfulness, perceived musical competence, and treatment expectancy, will be tested.
This study uses a mixed methods intervention design in which qualitative data (i.e.
semi-structured follow-up interviews) are embedded within a randomized controlled trial.
A total of 100 outpatients with advanced cancer and chronic bone pain will be randomized to one of two 6-week treatments: 1) Interactive Music Therapy or 2) Verbal-based support.
The mediators and pain outcomes will be measured at baseline and after the fourth and sixth session using self-report measures as well as biomarkers (salivary cortisol, lachrymal dopamine content, serum oxytocin, and plasma β-endorphins).
Follow-up interviews with a subsample of 30 participants will enable the investigators to examine the congruence between the hypothesized mediators and moderators and participant explanations of how IMT influences chronic pain management (i.e.
theory of action).
This study will contribute towards the optimization of music therapy for palliation of chronic pain in people with advanced cancer through a better understanding of the impact of mediators and moderators of IMT on chronic pain management.
The results of this study will provide estimated effects sizes of IMT on the mediators and preliminary effect size estimates for the pain outcomes.
This information will be instrumental in the development of a subsequent large-scale efficacy trial.
Study Type
Interventional
Enrollment (Actual)
103
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Pennsylvania
-
Philadelphia, Pennsylvania, United States, 19102
- Hahnemann University Hospital
-
Philadelphia, Pennsylvania, United States, 19107
- Thomas Jefferson Sidney Kimmel Cancer Center
-
Philadelphia, Pennsylvania, United States, 19124
- Cancer Treatment Centers of America (CTCA)
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- male or female outpatients with advanced cancer (Stage 3 & 4; or relapse refractory patients for myeloma)
- diagnosed with locally advanced cancer that has extended to organs/soft tissue or is impinging on or eroding the bone; or bone metastases or soft tissue metastasis
- moderate to severe pain with an average intensity ≥4 on a 0-10 Numeric Rating Scale (NRS)
- experiencing pain for ≥ 3 months
- Karnofsky Performance score of ≥ 60 or the Eastern Cooperative Group Performance Status (ECOG) equivalent of ≤ 2 (i.e. requires occasional assistance, but is able to care for most of their personal needs)
Exclusion Criteria:
- expected survival ≤ 3 months
- primary central nervous system (CNS) tumor or CNS metastatic disease that impairs concentration, memory, balance or focus that would preclude ability to participate in a 60 minute, recurring activity and completion of self-report measures
- hematologic malignancies except for myeloma which causes significant bone pain
- ≤ 3 weeks post-operation from start of study
- active psychosis or dementia
- inability to speak or write English
- moderate to severe hearing impairment
- current smoking
- current alcohol dependence
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Supportive Care
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Interactive Music Therapy
Six 45-minute individual interactive music therapy sessions.
|
Six 45-minute individual interactive music therapy (IMT) sessions delivered by a board-certified music therapist.
Sessions start with music-guided breathing, imagery, or humming.
The music therapist then engages the participant in singing of familiar songs and co-created vocal or instrumental music improvisations based on patient needs.
Discussion about the meaning assigned to songs and emotions expressed through the improvisations follow.
The IMT experiences are aimed at facilitating emotional expression, offering support through interactive music making, and strengthening inner resources of creativity.
In addition, each week the participant learns music-based techniques for self-management of anxiety, stress, mood, and pain.
|
Active Comparator: Verbal-based support
Six 45-minute individual verbal support sessions
|
Six 45-minute individual sessions delivered by a master's level clinician with training in counseling.
The sessions are focused on patient-initiated conversations about their pain, life stressors and the impact on their daily life.
The intervener provides nondirective, supportive care by offering supportive, validating statements and reflective listening.
The intervener refrains from employing active suggestion, problem-solving or behavioral or cognitive therapy techniques.
The verbal support sessions are aimed at providing an empathic, therapeutic environment to facilitate emotional expression and sharing of worries and fears.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Pain Intensity
Time Frame: through study completion, a maximum of 12 weeks
|
measured by PROMIS® Pain Intensity-Short Form (SF)3a
|
through study completion, a maximum of 12 weeks
|
Pain Interference
Time Frame: through study completion, a maximum of 12 weeks
|
measured by PROMIS® Cancer-Pain Interference -SF 6b
|
through study completion, a maximum of 12 weeks
|
Patient Perception of Change
Time Frame: through study completion, a maximum of 12 weeks
|
measured by Patient Global Impression of Change Scale (PGIC)
|
through study completion, a maximum of 12 weeks
|
Serum β-endorphin
Time Frame: through study completion, a maximum of 12 weeks
|
biomarker for pain intensity
|
through study completion, a maximum of 12 weeks
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Anxiety
Time Frame: through study completion, a maximum of 12 weeks
|
Mediator outcome measured by PROMIS® Cancer-Anxiety - SF
|
through study completion, a maximum of 12 weeks
|
Mood
Time Frame: through study completion, a maximum of 12 weeks
|
Mediator outcome measured by Positive and Negative Affect Scale (PANAS)
|
through study completion, a maximum of 12 weeks
|
Perceived support
Time Frame: through study completion, a maximum of 12 weeks
|
Mediator outcome measured by PROMIS® Emotional Support - SF 6a
|
through study completion, a maximum of 12 weeks
|
Self-efficacy
Time Frame: through study completion, a maximum of 12 weeks
|
Mediator outcome measured by PROMIS® Self-Efficacy of Symptoms
|
through study completion, a maximum of 12 weeks
|
Salivary cortisol
Time Frame: through study completion, a maximum of 12 weeks
|
Mediator outcome (biomarker for anxiety)
|
through study completion, a maximum of 12 weeks
|
Serum oxytocin
Time Frame: through study completion, a maximum of 12 weeks
|
Mediator outcome (biomarker for social support)
|
through study completion, a maximum of 12 weeks
|
Lachrymal dopamine
Time Frame: through study completion, a maximum of 12 weeks
|
Mediator outcome (biomarker for mood)
|
through study completion, a maximum of 12 weeks
|
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Treatment expectancy
Time Frame: Baseline
|
Moderator outcome measured by Credibility/Expectancy Questionnaire (CEQ)
|
Baseline
|
Perceived Musical Competence
Time Frame: Baseline
|
Moderator outcome measured by two-item questionnaire
|
Baseline
|
Adult playfulness
Time Frame: Baseline
|
Moderator outcome measured by Short Measure for Adult Playfulness (SMAP)
|
Baseline
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Collaborators
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
February 1, 2018
Primary Completion (Actual)
December 31, 2021
Study Completion (Actual)
December 31, 2021
Study Registration Dates
First Submitted
February 1, 2018
First Submitted That Met QC Criteria
February 7, 2018
First Posted (Actual)
February 14, 2018
Study Record Updates
Last Update Posted (Actual)
February 21, 2022
Last Update Submitted That Met QC Criteria
February 18, 2022
Last Verified
February 1, 2022
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- R01NR016681 (U.S. NIH Grant/Contract)
- 1R01NR016681-01A1 (U.S. NIH Grant/Contract)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
YES
IPD Plan Description
We will make the de-identified datasets available to other researchers.
Researchers will be asked to submit a formal request for data sharing to the PI that outlines the purpose of the secondary data analysis.
Data and associated documentation will be made available to users only under a data-sharing agreement that provides for: (1) a commitment to using the data only for research purposes; (2) a commitment to securing the data using appropriate computer technology; and (3) a commitment to destroying or returning the data after analyses are completed.
IPD Sharing Time Frame
After completion of study report and publication of results
IPD Sharing Access Criteria
We will make the de-identified datasets available to other researchers.
Researchers will be asked to submit a formal request for data sharing to the PI that outlines the purpose of the secondary data analysis.
Data and associated documentation will be made available to users only under a data-sharing agreement that provides for: (1) a commitment to using the data only for research purposes; (2) a commitment to securing the data using appropriate computer technology; and (3) a commitment to destroying or returning the data after analyses are completed.
IPD Sharing Supporting Information Type
- STUDY_PROTOCOL
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Advanced Cancer
-
STORM Therapeutics LTDRecruitingCancer | Advanced Solid Tumor | Advanced CancerUnited States
-
Merck Sharp & Dohme LLCCompletedAdvanced Cancer Relapsed | Advanced Cancer Refractory
-
Teon Therapeutics, Inc.Merck Sharp & Dohme LLCTerminatedCancer | Advanced Solid Tumor | Advanced Cancer | OncologyUnited States
-
BiOneCure Therapeutics Inc.RecruitingCancer | Advanced Solid Tumor | Advanced Cancer | OncologyUnited States
-
Zhejiang UniversityRecruitingAdvanced Colorectal Cancer | Advanced Hepatocellular Carcinoma | Advanced Gastric Cancer | Advanced Pancreatic CancerChina
-
PfizerTerminatedAdvanced Solid Tumors | Advanced CancerUnited States
-
Avera McKennan Hospital & University Health CenterCompleted
-
Vanderbilt-Ingram Cancer CenterNational Institutes of Health (NIH)Active, not recruitingAdvanced Cancer | Relapsed Cancer | Refractory CancerUnited States
-
AVEO Pharmaceuticals, Inc.CompletedAdvanced Cancer | Refractory CancerUnited States
-
University Health Network, TorontoUniversity of UlmRecruiting
Clinical Trials on Interactive Music Therapy
-
Yonsei UniversityCompletedCritically Ill Adult Patients in Intensive Care UnitsKorea, Republic of
-
Drexel UniversityCompleted
-
Children's Hospital of Eastern OntarioCanadian Diabetes AssociationCompletedObesity | Overweight With ComorbidityCanada
-
Case Comprehensive Cancer CenterCompletedMultiple Myeloma | Hodgkin Lymphoma | Non-Hodgkin LymphomaUnited States
-
University of North Carolina, Chapel HillNorth Carolina Translational and Clinical Sciences InstituteCompletedAutonomic Nervous System Imbalance | Hypothalamic Pituitary Adrenal Axis SuppressionUnited States
-
Wayne State UniversityCompletedNeurological DisordersUnited States
-
Icahn School of Medicine at Mount SinaiCompletedSARS-CoV 2 | Dyspnea | Post Covid-19 RespiratoryUnited States
-
Icahn School of Medicine at Mount SinaiCompleted
-
Children's Healthcare of AtlantaCompletedRespiratory Syncytial Virus InfectionsUnited States
-
University of MilanUnknownCritical Illness | Music Therapy | Hypnotics and SedativesItaly